UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/596,788	04/20/2007	Valerio Berdini	3073.006B	2889
	7590		EXAM	IINER
5 COLUMBIA CIRCLE WEST, THEODORE R ALBANY, NY 12203				EODORE R
ALDANI, NI	12205		ART UNIT	PAPER NUMBER
			1628	
			MAIL DATE	DELIVERY MODE
			05/06/2011	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)	
	10/596,788	BERDINI ET AL.	
Office Action Summary	Examiner	Art Unit	
	Theodore R. West	1628	
The MAILING DATE of this communication ap Period for Reply	ppears on the cover sheet with	the correspondence address	:
A SHORTENED STATUTORY PERIOD FOR REPLEWHICHEVER IS LONGER, FROM THE MAILING ID. - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period. Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICAL 136(a). In no event, however, may a report will apply and will expire SIX (6) MONTH te, cause the application to become ABA	ATION. ly be timely filed HS from the mailing date of this communic NDONED (35 U.S.C. § 133).	
Status			
1) ☐ Responsive to communication(s) filed on 23 c 2a) ☐ This action is FINAL . 2b) ☐ This action is FINAL . 2b) ☐ This action is application is in condition for allowed closed in accordance with the practice under	is action is non-final. ance except for formal matte	•	ts is
Disposition of Claims			
4) ✓ Claim(s) 76-108 is/are pending in the applicate 4a) Of the above claim(s) is/are withdrate 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ✓ Claim(s) 76-108 are subject to restriction and	awn from consideration.		
Application Papers			
9) The specification is objected to by the Examin 10) The drawing(s) filed on is/are: a) ac Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the E	cepted or b) objected to be e drawing(s) be held in abeyanc ction is required if the drawing(s	e. See 37 CFR 1.85(a).) is objected to. See 37 CFR 1.13	, ,
Priority under 35 U.S.C. § 119			
12) ☐ Acknowledgment is made of a claim for foreig a) ☐ All b) ☐ Some * c) ☐ None of: 1. ☐ Certified copies of the priority document 2. ☐ Certified copies of the priority document 3. ☐ Copies of the certified copies of the priority document application from the International Bureat * See the attached detailed Office action for a list	nts have been received. nts have been received in Ap ority documents have been re au (PCT Rule 17.2(a)).	plication No eceived in this National Stage	Э
Attachment(s)	1		
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 	Paper No(s)/	mmary (PTO-413) Mail Date ormal Patent Application -	

Art Unit: 1628

DETAILED ACTION

Applicant's preliminary amendment submitted on June 23, 2006 has been entered. Claims 76-108 are pending in the application and are subject to both restriction and a requirement for a species election as set forth below.

Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 76-104, drawn to compounds of formula (I) and compositions thereof.

Group II, claim(s) 105, drawn to methods for the prophylaxis or treatment of a disease state or condition mediated by protein kinase B using compounds of formula (I).

Group III, claim(s) 106, drawn to methods for treating a disease or condition comprising or arising from abnormal cell growth using compounds of formula (I).

Group IV, claim(s) 107, drawn to methods of inducing apoptosis in a cancer cell using compounds of formula (I).

Group V, claim(s) 108, drawn to processes for the preparation of compounds of formula (I).

The groups of inventions listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Although the groups

of claimed inventions require the technical feature of compounds according to formula (I), this technical feature is not a <u>special</u> technical feature as it does not make a contribution over the prior art in view of US Patent No. 6,200,978 B1 by Maw et al. Specifically, this references discloses (see "Preparation 48" at col. 119) a compound according to formula (I), wherein A is a hydrocarbon linker group having 1 carbon atom, E and R¹ are both phenyl groups, R² and R³ together with the nitrogen atom to which they are bound form a piperazine, and R⁴ and R⁵ are both hydrogen. As such, Maw et al. would serve as a basis for rejection of the pending claims as being either anticipated by or obvious over the prior art. Because the feature "formula (I)" of the claims is not a special technical feature within the meaning of PCT Rule 13, restriction is proper.

Species Election

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows: The Examples disclosed in applicant's specification at pp. 105-197, as well as the compounds recited in claim 102.

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election. Regardless

Application/Control Number: 10/596,788

Art Unit: 1628

of which Group is elected, the species election must identify one specific compound of formula (I), which shall be identified by chemical name or by chemical structure.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise require all the limitations of an allowed generic claim. Currently, the following claim(s) are generic: Claims 76-108.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse. Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable on the elected invention or species.

Should applicant traverse on the ground that the inventions have unity of invention (37 CFR 1.475(a)), applicant must provide reasons in support thereof.

Applicant may submit evidence or identify such evidence now of record showing the

inventions to be obvious variants or clearly admit on the record that this is the case. Where such evidence or admission is provided by applicant, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Rejoinder

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder.

All claims directed to a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product

MPEP § 804.01.

are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition

against double patenting rejections of 35 U.S.C. 121 does not apply where the

restriction requirement is withdrawn by the examiner before the patent issues. See

Page 6

Correspondence Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Theodore R. West whose telephone number is (571)270-5993. The examiner can normally be reached on Monday to Friday, 10:30 am to 7:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brandon J. Fetterolf can be reached on (571)272-2919. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for

Application/Control Number: 10/596,788 Page 7

Art Unit: 1628

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information

system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/T. R. W./ Examiner, Art Unit 1628

/Anish Gupta/ Primary Patent Examiner, Art Unit 1654